Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results